Data from A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer
Robert H. Jones(Velindre NHS Trust), Udai Banerji(Institute of Cancer Research), Mark Kowalski(College of San Mateo), Harriet S. Walter(Leicester Royal Infirmary), Louise Carter(The Christie NHS Foundation Trust), Ruth Plummer(National Health Service), Patricia Roxburgh(Beatson West of Scotland Cancer Centre), Elena Garralda(Memorial Sloan Kettering Cancer Center), Sarah P. Blagden(Churchill Hospital), Desamparados Roda(Institute of Cancer Research), Barbara Klencke, Alan Anthoney(St James's University Hospital), Rebecca Kristeleit(Guy's and St Thomas' NHS Foundation Trust), Víctor Moreno, Debashis Sarker(King's College - North Carolina), Hendrik‐Tobias Arkenau(Sarah Cannon Research Institute)
Cited by 0
Related Papers
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k